Trial Profile

Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Venetoclax (Primary) ; Ziftomenib (Primary)
Indications Acute myeloid leukaemia
Focus Registrational; Therapeutic Use
Acronyms KOMET-017; KOMET-017-NIC
Sponsors Kura Oncology

07 Jun 2025 Status changed from planning to not yet recruiting.
14 May 2025 According to a Kura Oncology media release, the company announced that an abstract of data from this study has been accepted for the online publication.
01 May 2025 According to a Kura Oncology media release, company to initiate the study in the second half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com